查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1717887

思觉失调症类型、治疗层级、作用机制、製剂类型、最终用户、患者环境、患者人口统计划分 - 2025-2030 年全球预测

Schizophrenia Therapeutics Market by Type, Therapeutic Class, Mechanism of Action, Formulation Type, End Users, Patient Settings, Patient Demographics - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年思觉失调症药物市场价值为55.9亿美元，2024年将达58.9亿美元，复合年增长率为5.47%，到2030年将达到81.2亿美元。

主要市场统计数据
基准年2023年 55.9亿美元
预计2024年 58.9亿美元
预测年份 2030 81.2亿美元
复合年增长率（%） 5.47%

管理和治疗思觉失调症一直是一个长期的挑战，需要对临床科学和患者照护有深入的了解。近几十年来，该领域的研究和实践取得了长足发展，将创新的科学方法与富有同情心的患者支持相结合。本执行摘要深入探讨了当前的治疗前景，重点介绍了治疗方法重塑治疗治疗方法的现有治疗方法和新兴疗法。

我们对神经生物学和心理健康的理解不断进步，从而增强了治疗通讯协定，并强调个人化医疗。新兴的临床见解加上正在进行的研究为相关人员提供了大量数据，从而改善了诊断、治疗计划和结果评估。该报告介绍了思觉失调症药物领域的主要趋势、细分、区域分析和公司绩效数据，旨在为决策者和专业人士提供全面的指南。

在快速发展的环境中，不断改进治疗方法至关重要。现在，相关人员比以往任何时候都更需要利用尖端策略，与研究机构、医疗保健提供者和产业合作伙伴密切合作，推动患者照护和临床结果的有意义的进步。

思觉失调症治疗的变革

思觉失调症药物治疗的最新趋势表明，模式转移融合了新的临床实践和技术创新。该行业正在经历变革时期，传统方法正在与先进的科学研究和数位健康解决方案相结合。创新的治疗方法、以患者为中心的护理模式和真实世界的证据正在全面重新定义预防策略和长期管理解决方案。

研究人员和临床医生越来越多地采用数位平台进行患者监测和诊断，从而提高治疗决策的准确性和效率。精准医疗技术与人工智慧的结合使得人们能够更深入地了解患者的反应，而来自临床研究的新兴数据则推动着治疗通讯协定的演变。这种动态转变正在为从急性护理到长期管理的连续护理铺平道路，从而改善患者的生活品质。

该行业现在面临多学科协作和跨职能洞察至关重要的未来。随着相关人员从传统的治疗方法转向更全面、技术主导的模式，整个医疗领域正在经历重大变革时期，这些模式有望提高治疗依从性、改善临床结果并持续促进医疗保健服务的成长。

对塑造市场格局的细分市场的详细洞察

对市场区隔的详细分析为了解思觉失调症药物的各个方面提供了宝贵的见解。从市场类型来看，非药物疗法和药物疗法都受到了广泛关注。在非药物治疗领域，认知行为疗法、电痉挛疗法和家庭治疗等方法在患者管理中越来越受到认可，为从整体角度解决心理健康问题提供了选择。在药理学方面，注射药物和口服药物的划分为针对不同患者需求和依从性因素的客製化治疗方法铺平了道路。

除了治疗方法类型之外，治疗层级之间也有明显区别：抗精神病药物、情绪稳定剂和选择性血清素再回收抑制剂。抗精神病药物特别分为第一代和第二代，反映了配方的演变及其对症状缓解和副作用的影响。根据临床疗效和个别患者反应情况，每类药物对治疗策略都有独特的贡献。

此外，根据作用机制分析细分时，还会出现更多细微差别。这些包括多巴胺受体拮抗剂、麸胺酸调变器以及血清素和多巴胺活性调变器，每种药物都表现出影响治疗结果的不同动态特性。此外，透过插入物和贴片、液体和固态锭剂的视角对配方类型进行了严格审查，强调了输送机制如何显着影响患者的依从性。细分策略也扩展到调查居家照护机构、医院、精神科诊所和研究机构等最终用户。最后，患者环境（无论是住院还是门诊病人）以及患者人口统计（包括成人、老年和儿童）提供了影响整体市场动态的不同患者概况的全面视图。每个细分参数都提供了精确的见解，帮助相关人员更好地了解市场的复杂性并相应地调整他们的策略。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球精神疾病盛行率上升
      • 扩大政府措施和宣传活动，提高人们对精神疾病的认识
    • 限制因素
      • 对产品召回和不利事件的担忧
    • 机会
      • 针对不同类型思觉失调症的标靶治疗进展
      • 口服抗精神病药物临床试验增加凸显其潜力
    • 任务
      • 抗精神病药物的副作用问题
  • 市场区隔分析
    • 类型：注射剂在持续释放药物方面的重要性日益凸显，有助于提高患者依从性
    • 治疗层级：具有更广泛作用机制的第二代抗精神病药物的采用日益增加。
    • 作用机转：藉由增加血清素活性并同时调节多巴胺，增强血清素和多巴胺活性调节剂的效果。
    • 配方类型：对于吞嚥困难或需要调整剂量的患者，液体溶液的需求日益增加
    • 最终使用者：多种治疗方法的综合护理计划扩大了思觉失调症药物在精神病诊所的应用
    • 病人环境：扩大思觉失调症物在住院治疗的益处
    • 患者人口统计：思觉失调症药物的个人化治疗方法对老年患者很重要
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章思觉失调症药物市场（按类型）

  • 非药物治疗
    • 认知行为治疗（CBT）
    • 电痉挛疗法（ECT）
    • 家庭治疗
  • 药物治疗
    • 注射药物
    • 口服药物

第七章思觉失调症药物市场（依治疗层级）

  • 抗精神病药物
    • 第一代抗精神病药物
    • 第二代抗精神病药物
  • 情绪稳定剂
  • 选择性血清素再回收抑制剂

第八章思觉失调症药物市场（依作用机制）

  • 多巴胺受体拮抗剂
  • 麸胺酸调变器
  • 血清素/多巴胺活性调节剂

第九章思觉失调症治疗药物市场（依处方类型）

  • 插入件和补丁
  • 液体溶液
  • 固态锭剂

第 10 章思觉失调症药物市场（按最终用户）

  • 居家照护环境
  • 医院
  • 心理健康诊所
  • 研究机构

第 11 章思觉失调症药物市场（依患者环境）

  • 住院护理
  • 门诊护理

第 12 章思觉失调症药物市场（依患者人口统计）

  • 成年患者
  • 老年患者
  • 儿科患者

13.美洲思觉失调症药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

14. 亚太地区思觉失调症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

15. 欧洲、中东和非洲思觉失调症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Delpor, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • GlaxoSmithKline plc.
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Vanda Pharmaceuticals Inc.
Product Code: MRR-8E22B61932B8

The Schizophrenia Therapeutics Market was valued at USD 5.59 billion in 2023 and is projected to grow to USD 5.89 billion in 2024, with a CAGR of 5.47%, reaching USD 8.12 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 5.59 billion
Estimated Year [2024] USD 5.89 billion
Forecast Year [2030] USD 8.12 billion
CAGR (%) 5.47%

The management and treatment of schizophrenia have long presented challenges that require a deep understanding of both clinical science and patient care. In recent decades, research and practice in this field have evolved significantly, combining innovative scientific approaches with compassionate patient support. This executive summary offers an in-depth exploration of the current therapeutics landscape, addressing both established and emerging modalities that are reshaping treatment paradigms.

Advancements in the understanding of neurobiology and mental health have led to enhanced treatment protocols that emphasize personalized care. Novel clinical insights, coupled with ongoing research, have provided stakeholders with a wealth of data, allowing for improved diagnosis, treatment planning, and outcome evaluation. This document aims to serve as a comprehensive guide for decision-makers and experts alike, presenting key trends, segmentation insights, regional analysis, and company performance data for a clear strategic focus in the field of schizophrenia therapeutics.

In this rapidly evolving environment, continuous improvement of therapeutic methodologies is imperative. Stakeholders are now, more than ever, encouraged to leverage cutting-edge strategies and collaborate closely with research institutions, healthcare providers, and industry partners to drive meaningful progress in patient care and clinical outcomes.

Transformative Shifts in Schizophrenia Therapeutics

Recent trends within the field of schizophrenia therapeutics have signaled a paradigm shift towards integrating both novel clinical practices and technological innovations. The industry is witnessing a transformative phase where traditional approaches are being augmented with advanced scientific research and digital health solutions. Innovative treatment methodologies, patient-centered care models, and real-world evidence have collectively redefined both preventative strategies and long-term management solutions.

Researchers and clinicians are increasingly adopting digital platforms for patient monitoring and diagnosis, thereby enhancing the accuracy and efficiency of treatment decisions. The integration of precision medicine techniques and artificial intelligence has allowed for more granular insights into patient responses, while emerging data from clinical studies is driving the evolution of therapeutic protocols. This dynamic shift is paving the way for a continuum of care that spans acute treatment phases to long-term management, ensuring a better quality of life for patients.

The industry now faces a future where interdisciplinary collaboration and cross-functional insights are essential. As stakeholders transition from conventional treatment regimens to more holistic, technology-driven models, the entire therapeutic landscape is undergoing a profound transformation that promises improved treatment adherence, superior clinical outcomes, and sustainable growth in healthcare delivery.

In-Depth Segmentation Insights Shaping the Market Landscape

A granular analysis of the market segmentation provides valuable insights into the diverse dimensions of schizophrenia therapeutics. By examining the market based on type, significant attention has been directed towards both non-pharmacological and pharmacological therapies. In the realm of non-pharmacological treatments, methods such as Cognitive-Behavioral Therapy, Electroconvulsive Therapy, and Family Therapy are playing an increasingly recognized role in patient management, offering alternatives that address mental health from a holistic standpoint. On the pharmacological front, the division into injectable and oral medications has paved the way for tailored treatment regimens that cater to different patient needs and compliance factors.

Beyond therapy types, the therapeutic class segmentation delineates a clear distinction among antipsychotics, mood stabilizers, and selective serotonin reuptake inhibitors. The antipsychotics category, in particular, is segmented further into first-generation and second-generation compounds, reflecting the evolution of drug formulations and their impact on symptomatic relief and side effect profiles. Each class contributes uniquely to treatment strategies, informed by clinical efficacy and individual patient response profiles.

Further nuances emerge when the segmentation is analyzed based on the mechanism of action. This includes an emphasis on dopamine receptor antagonists, glutamate modulators, and serotonin dopamine activity modulators, each indicative of a distinct pharmacodynamic property that influences therapeutic outcomes. Additionally, formulation type is critically examined through the lenses of inserts and patches, liquid solutions, and solid tablets, revealing how delivery mechanisms can significantly affect patient adherence. The segmentation strategy also extends to the exploration of end users across homecare settings, hospitals, mental health clinics, and research institutes. Lastly, patient settings, whether inpatient or outpatient care, and patient demographics, including adult, geriatric, and pediatric patients, provide a comprehensive view of the diverse patient profiles that influence the overall market dynamic. Each segmentation parameter offers precise insights that help stakeholders better understand the market's complexity and tailor strategies accordingly.

Based on Type, market is studied across Non-Pharmacological Therapies and Pharmacological Therapies. The Non-Pharmacological Therapies is further studied across Cognitive-Behavioral Therapy (CBT), Electroconvulsive Therapy (ECT), and Family Therapy. The Pharmacological Therapies is further studied across Injectable Medications and Oral Medications.

Based on Therapeutic Class, market is studied across Antipsychotics, Mood Stabilizers, and Selective Serotonin Reuptake Inhibitors. The Antipsychotics is further studied across First-Generation Antipsychotics and Second-Generation Antipsychotics.

Based on Mechanism of Action, market is studied across Dopamine Receptor Antagonists, Glutamate Modulators, and Serotonin Dopamine Activity Modulators.

Based on Formulation Type, market is studied across Inserts and Patches, Liquid Solutions, and Solid Tablets.

Based on End Users, market is studied across Homecare Settings, Hospitals, Mental Health Clinics, and Research Institutes.

Based on Patient Settings, market is studied across Inpatient Care and Outpatient Care.

Based on Patient Demographics, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Key Regional Insights Influencing Market Dynamics

A regional perspective unveils critical differences and emerging opportunities within the global schizophrenia therapeutics market. In the Americas, the landscape is marked by a robust integration of clinical research and a strong emphasis on innovation, with established healthcare infrastructures supporting wide-spread adoption of both traditional and emerging treatment modalities. These markets benefit from a well-developed environment of regulatory support, a competitive pharmaceutical industry, and active investments in mental health research, which collectively drive the adoption of new therapies.

Turning attention to regions spanning Europe, the Middle East, and Africa, one finds a diverse mix of market conditions. European nations, with their long-standing traditions in clinical research and high-quality healthcare provisions, lead in the adoption of innovative therapeutics, bridging the gap between novel scientific breakthroughs and patient care. Simultaneously, regions in the Middle East and Africa are rapidly evolving, with increasing investments in healthcare infrastructure and a growing focus on mental health awareness. The dynamic interplay between emerging markets and traditional systems in these areas presents both challenges and significant growth opportunities.

In the Asia-Pacific region, the market is characterized by rapid development and a surge in research investments. This region stands out for its expanding patient base coupled with an evolving regulatory framework, which together create a fertile environment for the introduction and acceptance of advanced therapeutic solutions. The collective insights from these regions reveal a complex, yet opportunistic global market where varying socio-economic and regulatory factors converge, ultimately driving both competitive intensity and innovation in schizophrenia therapeutics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Comprehensive Analysis of Key Company Performances

An analysis of the leading companies in schizophrenia therapeutics offers a window into competitive dynamics and strategic innovations within the market. Prominent firms such as AbbVie Inc., Acadia Pharmaceuticals Inc., Alkermes Plc, and Amneal Pharmaceuticals, LLC have established themselves as benchmarks in the pursuit of novel treatment paradigms. Esteemed organizations like Astellas Pharma Inc., AstraZeneca plc, and BioXcel Therapeutics, Inc. continue to invest heavily in research and development, ensuring that their therapeutic portfolios remain at the forefront of innovation.

In addition, companies including Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Limited, and Delpor, Inc. are recognized for their commitment to clinical excellence and the introduction of next-generation therapies. Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, and Gedeon Richter Plc further reinforce the market's competitive behavior by continually adapting to evolving clinical guidelines and market demands.

Other influential players such as GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Lundbeck A/S, and Lupin Limited, alongside emerging innovators like Luye Pharma Group Ltd, Lyndra Therapeutics Inc, and Meiji Holdings Co., Ltd., are leveraging strategic partnerships and technological advancements to extend their market reach. The industry is also shaped by the contributions of Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Reviva Pharmaceuticals Holdings, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Vanda Pharmaceuticals Inc. Each of these companies brings a unique blend of innovation, expertise, and a commitment to patient care, collectively driving a proactive evolution in therapeutic solutions across the market.

The report delves into recent significant developments in the Schizophrenia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Acadia Pharmaceuticals Inc., Alkermes Plc, Amneal Pharmaceuticals, LLC, Astellas Pharma Inc., AstraZeneca plc, BioXcel Therapeutics, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Limited, Delpor, Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Gedeon Richter Plc, GlaxoSmithKline plc., Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Lundbeck A/S, Lupin Limited, Luye Pharma Group Ltd, Lyndra Therapeutics Inc, Meiji Holdings Co., Ltd., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Reviva Pharmaceuticals Holdings, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Vanda Pharmaceuticals Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are advised to adopt a multifaceted strategy designed to harness emerging trends and foster sustainable growth in the schizophrenia therapeutics market. Decision-makers should prioritize an expansive research and development agenda that integrates the latest breakthroughs in pharmacological and non-pharmacological treatments. Fostering a culture of innovation through cross-functional collaborations and strategic partnerships will be imperative for staying ahead of evolving clinical standards.

Investments in digital health technologies and data analytics are also crucial for improving patient outcome analytics and ensuring that treatment protocols are timely, effective, and responsive to patient needs. Leaders should engage with healthcare practitioners, academic researchers, and technology innovators to build robust platforms that support advanced diagnostic and therapeutic tools. Building these collaborations not only enhances research capabilities but also enables companies to adapt quickly to regulatory changes and evolving market expectations.

Additionally, a proactive engagement with regulatory bodies and patient advocacy groups will be essential in creating an environment conducive to the rapid adoption of novel therapies. By capitalizing on the comprehensive insights provided through detailed market segmentation, regional explorations, and competitive company analyses, industry stakeholders can tailor their strategies to address both current challenges and future opportunities. A commitment to continuous learning, adaptive strategies, and patient-centered innovations will place industry leaders at the forefront of the therapeutic evolution in schizophrenia, ultimately leading to enhanced market performance and improved patient outcomes.

Conclusion: Synthesizing Market Trends and Future Prospects

The landscape of schizophrenia therapeutics is witnessing a rapid evolution characterized by technological innovation, comprehensive segmentation strategies, and active global participation. An integration of non-pharmacological and pharmacological treatments, supported by detailed analysis and robust regional insights, has provided stakeholders with a holistic view of the market dynamics. These trends not only highlight the progress made but also shed light on areas where further innovations could potentially reshape patient care.

In approaching the complexities of this market, the synthesis of intricate segmentation details and expansive regional insights reveals a promising yet challenging environment. The competitive spirit of leading pharmaceutical and biotechnological companies underscores the importance of a coordinated global strategy. As initiatives align more closely with advanced data analytics, digital strategies, and innovative treatment options, the future of schizophrenia therapeutics appears poised for remarkable transformation.

Overall, the clinical and market landscapes are converging to create an ecosystem where research, innovation, and patient-centered care operate in harmony. The strategic insights outlined reinforce the idea that a proactive, informed, and agile approach will be essential for stakeholders aiming to capture market opportunities and set new benchmarks in therapeutic excellence.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of mental health disorders across the globe
      • 5.1.1.2. Growing government initiatives and campaigns for awareness of mental illness
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with the product recall and adverse findings in medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements for developing targeted therapies for different types of schizophrenia
      • 5.1.3.2. Rising potential with increasing clinical trials for oral antipsychotic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to adverse side effects associated with antipsychotic drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing significance of injectable medications for sustained release of medication that can enhance adherence
    • 5.2.2. Therapeutic Class: Increasing adoption of second-generation antipsychotics for broader mechanism of action that targets
    • 5.2.3. Mechanism of Action: Growing benefits of serotonin dopamine activity modulators owing to enhancing serotonin activity while simultaneously modulating dopamine
    • 5.2.4. Formulation Type: Growing need of liquid solutions due to swallowing difficulties or those requiring dose adjustments
    • 5.2.5. End Users: Extending applications of schizophrenia therapeutics in mental health clinics owing to comprehensive care plans for various therapeutic modalities
    • 5.2.6. Patient Settings: Proliferating benefits of schizophrenia therapeutics medications for inpatient care
    • 5.2.7. Patient Demographics: High importance of schizophrenia therapeutics for geriatric patients owing to tailored therapeutic approaches
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Schizophrenia Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Therapies
    • 6.2.1. Cognitive-Behavioral Therapy (CBT)
    • 6.2.2. Electroconvulsive Therapy (ECT)
    • 6.2.3. Family Therapy
  • 6.3. Pharmacological Therapies
    • 6.3.1. Injectable Medications
    • 6.3.2. Oral Medications

7. Schizophrenia Therapeutics Market, by Therapeutic Class

  • 7.1. Introduction
  • 7.2. Antipsychotics
    • 7.2.1. First-Generation Antipsychotics
    • 7.2.2. Second-Generation Antipsychotics
  • 7.3. Mood Stabilizers
  • 7.4. Selective Serotonin Reuptake Inhibitors

8. Schizophrenia Therapeutics Market, by Mechanism of Action

  • 8.1. Introduction
  • 8.2. Dopamine Receptor Antagonists
  • 8.3. Glutamate Modulators
  • 8.4. Serotonin Dopamine Activity Modulators

9. Schizophrenia Therapeutics Market, by Formulation Type

  • 9.1. Introduction
  • 9.2. Inserts and Patches
  • 9.3. Liquid Solutions
  • 9.4. Solid Tablets

10. Schizophrenia Therapeutics Market, by End Users

  • 10.1. Introduction
  • 10.2. Homecare Settings
  • 10.3. Hospitals
  • 10.4. Mental Health Clinics
  • 10.5. Research Institutes

11. Schizophrenia Therapeutics Market, by Patient Settings

  • 11.1. Introduction
  • 11.2. Inpatient Care
  • 11.3. Outpatient Care

12. Schizophrenia Therapeutics Market, by Patient Demographics

  • 12.1. Introduction
  • 12.2. Adult Patients
  • 12.3. Geriatric Patients
  • 12.4. Pediatric Patients

13. Americas Schizophrenia Therapeutics Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Schizophrenia Therapeutics Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Schizophrenia Therapeutics Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Intra-cellular therapies reports positive phase 3 results for CAPLYTA in schizophrenia relapse prevention
    • 16.3.2. Teva unveils promising results from SOLARIS trial and real-world UZEDY analysis for schizophrenia treatment
    • 16.3.3. Leal therapeutics secures USD 45 million to advance schizophrenia and CNS disorder therapies
    • 16.3.4. Monument Therapeutics secures GBP 1M investment to advance schizophrenia treatment
    • 16.3.5. FDA approves Bristol Myers Squibb's new muscarinic agonist COBENFY for adults
    • 16.3.6. AbbVie's acquisition of Cerevel enhances its neuroscience pipeline and increase schizophrenia therapeutics
    • 16.3.7. FDA aligns with Reviva pharmaceuticals on brilaroxazine phase 3 trials for schizophrenia
    • 16.3.8. Lupin gains FDA approval for generic aripiprazole tablets, expanding U.S. CNS Presence
    • 16.3.9. Bristol Myers Squibb's acquisition of Karuna Therapeutics enhances schizophrenia treatment landscape
    • 16.3.10. Boehringer Ingelheim's schizophrenia treatment secures FDA breakthrough therapy status
    • 16.3.11. Lyndra Therapeutics reports positive phase 3 outcomes for oral weekly risperidone in schizophrenia
    • 16.3.12. Karuna Therapeutics' KarXT receives FDA NDA acceptance for schizophrenia treatment
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. Sanofi S.A.
    • 16.4.2. Lupin Limited
    • 16.4.3. Boehringer Ingelheim International GmbH
    • 16.4.4. Bristol-Myers Squibb and Company

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Acadia Pharmaceuticals Inc.
  • 3. Alkermes Plc
  • 4. Amneal Pharmaceuticals, LLC
  • 5. Astellas Pharma Inc.
  • 6. AstraZeneca plc
  • 7. BioXcel Therapeutics, Inc.
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol Myers Squibb Company
  • 10. Cipla Limited
  • 11. Delpor, Inc.
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. Eli Lilly and Company
  • 14. Gedeon Richter Plc
  • 15. GlaxoSmithKline plc.
  • 16. Glenmark Pharmaceuticals Limited
  • 17. Johnson & Johnson Services, Inc.
  • 18. Lundbeck A/S
  • 19. Lupin Limited
  • 20. Luye Pharma Group Ltd
  • 21. Lyndra Therapeutics Inc
  • 22. Meiji Holdings Co., Ltd.
  • 23. Merck & Co., Inc.
  • 24. Neurocrine Biosciences, Inc.
  • 25. Novartis AG
  • 26. Otsuka Holdings Co., Ltd.
  • 27. Pfizer Inc.
  • 28. Reviva Pharmaceuticals Holdings, Inc.
  • 29. Sanofi S.A
  • 30. Sumitomo Pharma Co., Ltd.
  • 31. Sun Pharmaceutical Industries Limited
  • 32. Takeda Pharmaceutical Company Limited
  • 33. Teva Pharmaceutical Industries Ltd.
  • 34. Torrent Pharmaceuticals Ltd.
  • 35. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. SCHIZOPHRENIA THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SCHIZOPHRENIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 298. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 308. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309.